BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...Machielse as EVP, CMC and Frank Czworka as SVP, global sales. Machielse was CEO of Vtesse Inc....
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013 ). In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...A/S (NASDAQ:ASND). Cydan Development Inc. , Cambridge, Mass. Chris Lieu IMR-687 VTS-270 Ascendis Pharma A/S Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...
BioCentury | Oct 20, 2017
Finance

Fast inflections

...for Cydan. The Vtesse experience has shown that that’s possible,” said Agarwala. Cydan’s first spinout, Vtesse Inc....
...up front by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) in April, about two years after its launch. Vtesse...
...additional spinouts, and expects to announce its third newco next year. Virginia Li, Staff Writer Cydan Development Inc. Vtesse Inc. Longitude...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013) . In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...Svenstrup was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Chris Lieu IMR-687 VTS-270 Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...
BioCentury | Apr 7, 2017
Finance

Right place, right time

...each company while giving Vtesse investors an exit and a share of any upside. The Vtesse...
...cost more than expected, while VTS-270 helps fill a hole in Sucampo’s pipeline. Sucampo acquired Vtesse...
...disease Priority Review voucher, Vtesse shareholders would receive an undisclosed portion of the net proceeds. Vtesse...
BioCentury | Apr 6, 2017
Company News

Vtesse, Sucampo deal

...Sucampo acquired rare disease company Vtesse for $200 million. Vtesse shareholders are to receive $170 million...
...and 2.8 million Sucampo shares up front, plus mid-single to double-digit royalties. Sucampo will gain Vtesse's...
...Mass.). Vtesse Inc. , Gaithersburg, Md. Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Rockville, Md. Business: Endocrine/Metabolic Chris Lieu VTS-270 Sucampo Pharmaceuticals Inc. Vtesse Inc....
BioCentury | Apr 3, 2017
Company News

Sucampo acquires rare disease play Vtesse

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired rare disease company Vtesse Inc. (Gaithersburg, Md.) for $200 million. Vtesse shareholders...
...million in cash and 2.8 million Sucampo shares up front, plus royalties. Sucampo will gain Vtesse's...
...Vtesse has set aside $1.7 million for the foundation, and Sucampo will match the contribution. Vtesse...
BioCentury | Mar 16, 2017
Clinical News

VTS-270: Completed Ph IIb/III enrollment

...about 51 patients, including those from the first part. The trial includes an open-label extension. Vtesse Inc....
...Status: Completed Phase IIb/III enrollment Milestone: Phase IIb/III data (early 2018); submit regulatory application (2018) Julian Zhu 2-hydroxypropyl-b-cyclodextrin HPBCD VTS-270 Vtesse Inc....
Items per page:
1 - 10 of 27
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

...Machielse as EVP, CMC and Frank Czworka as SVP, global sales. Machielse was CEO of Vtesse Inc....
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...EU. Sucampo gained the 2-hydroxypropyl-b-cyclodextrin targeting cholesterol and sphingolipid storage through its April acquisition of Vtesse Inc....
BioCentury | Oct 20, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013 ). In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...A/S (NASDAQ:ASND). Cydan Development Inc. , Cambridge, Mass. Chris Lieu IMR-687 VTS-270 Ascendis Pharma A/S Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...
BioCentury | Oct 20, 2017
Finance

Fast inflections

...for Cydan. The Vtesse experience has shown that that’s possible,” said Agarwala. Cydan’s first spinout, Vtesse Inc....
...up front by Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) in April, about two years after its launch. Vtesse...
...additional spinouts, and expects to announce its third newco next year. Virginia Li, Staff Writer Cydan Development Inc. Vtesse Inc. Longitude...
BioCentury | Oct 17, 2017
Financial News

Orphan drug accelerator Cydan raises $34M

...DMD). In 2013, Cydan raised a total of $26 million. The accelerator launched two companies: Vtesse Inc....
...Cambridge, Mass.) (see BioCentury, April 15, 2013) . In April, Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired Vtesse...
...Svenstrup was director of CMC at Ascendis Pharma A/S (NASDAQ:ASND). Chris Lieu IMR-687 VTS-270 Bristol-Myers Squibb Co. Cydan Development Inc. Imara Inc. Vtesse Inc. Phosphodiesterase-9...
BioCentury | Apr 7, 2017
Finance

Right place, right time

...each company while giving Vtesse investors an exit and a share of any upside. The Vtesse...
...cost more than expected, while VTS-270 helps fill a hole in Sucampo’s pipeline. Sucampo acquired Vtesse...
...disease Priority Review voucher, Vtesse shareholders would receive an undisclosed portion of the net proceeds. Vtesse...
BioCentury | Apr 6, 2017
Company News

Vtesse, Sucampo deal

...Sucampo acquired rare disease company Vtesse for $200 million. Vtesse shareholders are to receive $170 million...
...and 2.8 million Sucampo shares up front, plus mid-single to double-digit royalties. Sucampo will gain Vtesse's...
...Mass.). Vtesse Inc. , Gaithersburg, Md. Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP), Rockville, Md. Business: Endocrine/Metabolic Chris Lieu VTS-270 Sucampo Pharmaceuticals Inc. Vtesse Inc....
BioCentury | Apr 3, 2017
Company News

Sucampo acquires rare disease play Vtesse

...Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) acquired rare disease company Vtesse Inc. (Gaithersburg, Md.) for $200 million. Vtesse shareholders...
...million in cash and 2.8 million Sucampo shares up front, plus royalties. Sucampo will gain Vtesse's...
...Vtesse has set aside $1.7 million for the foundation, and Sucampo will match the contribution. Vtesse...
BioCentury | Mar 16, 2017
Clinical News

VTS-270: Completed Ph IIb/III enrollment

...about 51 patients, including those from the first part. The trial includes an open-label extension. Vtesse Inc....
...Status: Completed Phase IIb/III enrollment Milestone: Phase IIb/III data (early 2018); submit regulatory application (2018) Julian Zhu 2-hydroxypropyl-b-cyclodextrin HPBCD VTS-270 Vtesse Inc....
Items per page:
1 - 10 of 27